Core Viewpoint - Zoetis Inc. reported strong fourth-quarter results for 2025, exceeding earnings expectations and demonstrating resilience across its product portfolio despite challenges in certain segments [1][5]. Financial Performance - Adjusted earnings per share for Q4 2025 were $1.48, surpassing the consensus estimate of $1.40 [1]. - Total sales reached $2.387 billion, reflecting a 3% year-over-year increase, closely aligning with the consensus of $2.36 billion [1]. - Adjusted net income was $648 million, marking a 3% increase on a reported basis and a 4% increase on an organic operational basis [1][2]. Segment Breakdown - U.S. segment revenue was $1.2 billion, down 2% on a reported basis but flat on an organic operational basis [3]. - Companion animal product sales decreased by 1%, with declines in monoclonal antibody products for osteoarthritis partially offset by growth in parasiticides and dermatology [3]. - Livestock product sales declined by 6% on a reported basis due to divestitures, but increased by 3% on an organic operational basis, driven by growth in cattle and poultry biologics [4]. Future Guidance - For fiscal 2026, Zoetis forecasts adjusted earnings of $7.00-$7.10 per share, exceeding the consensus of $6.80 [6]. - Sales projections for 2026 are between $9.83 billion and $10.03 billion, compared to the consensus of $9.91 billion [6]. Analyst Outlook - Analysts from William Blair noted that the 2026 EPS guidance is above market expectations, suggesting potential stabilization in fundamentals [7]. - Concerns were raised regarding growth in key segments such as dermatology and OA pain, which experienced a decline [7][8]. - The competitive landscape is expected to intensify, raising questions about growth and EPS improvement in 2026 [8].

Friedrich Merz’s advisers trimmed their German growth forecast for next year to below 1%, underscoring the scale of challenge the chancellor faces in restoring meaningful expansion to Europe’s biggest economy. https://t.co/fuiPcLtB1e ...